Low-dose Lumigan launched for glaucoma

Lumigan (bimatoprost) eye drops are now available in a new lower-strength presentation. The new 0.1mg/ml drops effectively lower intraocular pressure (IOP), with comparable efficacy to and greater tolerability than the existing 0.3mg/ml drops.

Lumigan is indicated for use, either as monotherapy or with β-blockers, to reduce elevated IOP in adults with chronic open-angle glaucoma or ocular hypertension.

Bimatoprost is a prostaglandin analogue. It reduces IOP by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.

A pivotal, 12-month, randomised, controlled trial showed bimatoprost 0.1mg/ml to be equivalent in efficacy to bimatoprost 0.3mg/ml for the once-daily treatment of glaucoma or ocular hypertension. Both preparations reduced mean IOP by approximately 30% after 12 months.1

Patients treated with bimatoprost 0.1mg/ml were significantly less likely to experience treatment-related ocular adverse events than those treated with bimatoprost 0.3mg/ml (37.8% versus 50.3%; p=0.016). The relative risk of treatment discontinuation due to ocular adverse effects was 66 per cent lower in the bimatoprost 0.1mg/ml group than in the bimatoprost 0.3mg/ml group.

REFERENCES

  1. Cohen JS et al. Poster presented at 8th Congress of the European Glaucoma Society. Berlin, Germany, June 2008; P106.

View Lumigan drug record

Further information: Allergan

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more